A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Pavlina Spiliopoulou, Sarah P. Blagden, Lucinda Griffiths et al.|Journal of Experimental & Clinical Cancer Research|2024Cited by 8